Zacks: Brokerages Expect Evoke Pharma Inc (EVOK) to Post -$0.07 EPS

Share on StockTwits

Equities research analysts expect that Evoke Pharma Inc (NASDAQ:EVOK) will report earnings per share of ($0.07) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Evoke Pharma’s earnings. Evoke Pharma reported earnings of ($0.24) per share in the same quarter last year, which suggests a positive year over year growth rate of 70.8%. The business is scheduled to announce its next quarterly earnings report on Tuesday, November 13th.

According to Zacks, analysts expect that Evoke Pharma will report full year earnings of ($0.42) per share for the current financial year, with EPS estimates ranging from ($0.43) to ($0.40). For the next financial year, analysts expect that the company will post earnings of ($0.57) per share, with EPS estimates ranging from ($0.83) to ($0.31). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Thursday, August 9th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.02.

Several analysts have recently weighed in on the company. ValuEngine upgraded Evoke Pharma from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. HC Wainwright set a $9.00 price objective on Evoke Pharma and gave the company a “buy” rating in a report on Friday, August 17th. Finally, Zacks Investment Research downgraded Evoke Pharma from a “buy” rating to a “hold” rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $6.69.

In related news, major shareholder Lvp Gp Iii, Llc bought 500,000 shares of Evoke Pharma stock in a transaction dated Monday, August 20th. The stock was acquired at an average cost of $2.35 per share, with a total value of $1,175,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.94% of the company’s stock.

Shares of Evoke Pharma stock traded up $0.02 during trading on Friday, hitting $2.59. The stock had a trading volume of 60,547 shares, compared to its average volume of 75,392. The firm has a market cap of $43.43 million, a price-to-earnings ratio of -3.12 and a beta of 1.47. Evoke Pharma has a fifty-two week low of $1.85 and a fifty-two week high of $4.09.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with's FREE daily email newsletter.

Leave a Reply